7 news items
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
ALGM
ALKS
ALLR
24 Jul 24
. (NASDAQ:SAGE) dipped 17.8% to $10.75 after the Phase 2 KINETIC 2 study of SAGE-324 did not demonstrate a statistically significant dose-response
Alkermes plc Reports Second Quarter 2024 Financial Results
ALKS
24 Jul 24
, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release
6 Analysts Assess Alkermes: What You Need To Know
ALKS
15 Jul 24
their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Alkermes. This offers
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
ALKS
3 Jun 24
doses tested, with a clear dose response.Treatment with ALKS 2680 resulted in statistically significant
7 Analysts Assess Alkermes: What You Need To Know
ALKS
2 May 24
Key Insights:
Action Taken: In response to dynamic market conditions and company performance
iiibgrxr ni8u7fp
ALKS
2 May 24
statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating
5u07osmxlb42ewi4wnn96cidb0uokjseeegdg6txx29l425gstcupov40
ALKS
1 May 24
or responsibility for updating or revising any forward-looking statements contained in this press release
- Prev
- 1
- Next